Publications

Safety and Efficacy Findings from the Open-Label, Multicenter, Phase 3B, Expanded Treatment Protocol Study of Ruxolitinib for Treatment of Patients with Polycythemia Vera Who Are Resistant/Intolerant to Hydroxyurea and for Whom No Alternative Treatments Are Available

AuthID
P-00R-J33

Author(s)

Foltz, L

Pica, GM

Zerazhi, H

Van Droogenbroeck, J

Visanica, S

de la Fuente, EB

Leber, B

de Almeida, AM

Ranta, D

Kiladjian, JJ

Chrit, L

Kandra, A

Morando, J

Devos, T

Document Type

Article

Year published

2019

Published

in LEUKEMIA & LYMPHOMA, ISSN: 1042-8194

Volume: 60, Issue: 14, Pages: 3493-3502 (10)

Indexing

Wos^®

Scopus^®

Crossref^®6

Pubmed^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1080/10428194.2019.1636985

Pubmed: 31359808

Scopus: 2-s2.0-85077097704

Wos: WOS:000479548900001

Source Identifiers

ISSN: 1042-8194

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Safety and Efficacy Findings from the Open-Label, Multicenter, Phase 3B, Expanded Treatment Protocol Study of Ruxolitinib for Treatment of Patients with Polycythemia Vera Who Are Resistant/Intolerant to Hydroxyurea and for Whom No Alternative Treatments Are Available

Useful Links

Get Help

Federated Authentication (Click on the image)

Safety and Efficacy Findings from the Open-Label, Multicenter, Phase 3B, Expanded Treatment Protocol Study of Ruxolitinib for Treatment of Patients with Polycythemia Vera Who Are Resistant/Intolerant to Hydroxyurea and for Whom No Alternative Treatments Are Available

Useful Links

Get Help